Depression

From evidence-based novel therapies for bipolar depression to potential indicators of early-stage Alzheimer disease, here are highlights from the week in Psychiatric Times.

Here’s why most of the claims recently made about antidepressants in Newsweek are wrong.

The drug is in development for the treatment of acute depressive disorders and depression with suicidality.

In this CME article, learn how to apply novel treatment approaches for patients with bipolar depression.

Postpartum depression and major depressive disorder in pregnant and postpartum women are severely underdiagnosed and undertreated. How can we more effectively help this patient population?

Is there one state-of-the-art treatment for depression?

D for Depression? Researchers performed a 12-week, randomized, double-blind placebo-controlled trial of vitamin D augmentation for major depression with vitamin D deficiency.

A single dose of psilocybin could help patients with treatment-resistant depression, according to a new study.

According to new research, treating depression in older adults could decrease risk of dementia by 51%.

“Fishing” for novel approaches to depression: Researchers performed randomized dose-finding trial of omega-3 fatty acids for depression with inflammation.

At-home ketamine treatment initiated by an online provider presents many legal, clinical, and ethical challenges...

From older age bipolar disorder to the relationship between antidepressants and emotional numbing, here are highlights from the week in Psychiatric Times.

As patients improve with antidepressant treatment, emotional numbing decreases.

A new—cough, cough—combination treatment for depression. Researchers performed an RCT of dextromethorphan-bupropion in major depressive disorder.

From historic USPSTF draft screening recommendations to the need for novel treatments for bipolar depression, here are highlights from the week in Psychiatric Times.

In this CME article, learn more about the rationale for considering novel treatments for patients with bipolar depression.

The experts weighed in on a wide variety of psychiatric issues for the August 2022 issue of Psychiatric Times.

What is the optimal dose of aripiprazole as augmentation for treatment-refractory depression? Researchers performed a systematic review and dose-effect meta-analysis.

In this CME article, examine how current DSM nosology defines the proper method of assessing a mixed-episode patient and which diagnostic labels to give them based on their presenting symptomatology.

Dextromethorphan HBr -bupropion HCl extended-release tablets for the treatment of major depressive disorder just became FDA approved.

Treating women of reproductive age who have depression can be difficult. Here’s an overview on the subject from the 2022 Annual Psychiatric Times™ World CME Conference.

What are the latest treatments in difficult to treat depression?

Is it prolonged grief or MDD? Expert shares insights at premiere annual meeting.

Further evidence-based antidepressant treatments are needed for children and adolescents with depression.

The SSRIs’ mechanism of action is no index of safety and efficacy.